PC
TLOG

PointState Capital’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

PointState Capital’s Portfolio TLOG Stock Details TLOG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-240,000
Closed -$2.29M – 175
2013
Q4 		$2.29M Buy
+240,000
New +$1.87M 0.03% 130

Other funds holding TLOG

CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
FWC
First Washington Corp Seattle, Washington $353M AUM 41.46% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
PRCM
Pine River Capital Management Minnetonka, Minnesota $32.9M AUM 4.47% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

PointState Capital's TLOG Position: Q1 2014 in Review

PointState Capital sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q1 2014, closing a stake of 240,000 shares — an estimated $2.29M sold.

PointState Capital first reported a position in TLOG in Q4 2013 and held it in 1 quarter. The position peaked at $2.29M in Q4 2013. 35 funds tracked by Wall St. Rank hold TLOG as of Q1 2014.

  • PointState Capital reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q1 2014 after selling out during the quarter.
  • PointState Capital sold 240,000 TetraLogic Pharmaceuticals Corporation shares in Q1 2014, an estimated $2.29M.
  • PointState Capital first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 1 quarter.
  • PointState Capital's TetraLogic Pharmaceuticals Corporation position peaked at $2.29M in Q4 2013.
  • 35 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q1 2014.

Based on PointState Capital's 13F filing for Q1 2014, filed 15 May 2014.